Impact of pharmacogenomic DPYD variant guided dosing on toxicity in patients receiving fluoropyrimidines for gastrointestinal cancers in a high-volume tertiary centre

BACKGROUND: Dihydropyrimidine dehydrogenase (DPD) is a key enzyme in the metabolism of fluoropyrimidines. Variations in the encoding DPYD gene are associated with severe fluoropyrimidine toxicity and up-front dose reductions are recommended. We conducted a retrospective study to evaluate the impact...

Descripción completa

Detalles Bibliográficos
Autores principales: Lau, David K., Fong, Caroline, Arouri, Faten, Cortez, Lillian, Katifi, Hannah, Gonzalez-Exposito, Reyes, Razzaq, Muhammad Bilal, Li, Su, Macklin-Doherty, Aislinn, Hernandez, Monica Arenas, Hubank, Michael, Fribbens, Charlotte, Watkins, David, Rao, Sheela, Chau, Ian, Cunningham, David, Starling, Naureen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10131438/
https://www.ncbi.nlm.nih.gov/pubmed/37101114
http://dx.doi.org/10.1186/s12885-023-10857-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10131438/
https://www.ncbi.nlm.nih.gov/pubmed/37101114
http://dx.doi.org/10.1186/s12885-023-10857-8

Ejemplares similares